Innocan Pharma announces the inauguration of its drug development laboratory at Biohouse in the Hadassah Medical Center in Jerusalem

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – January 17, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Society” Where “Innocan“) is pleased to announce that it has inaugurated its first and new drug research and development laboratory at Biohouse Labs at Hadassah Medical Center in Jerusalem to accelerate the company’s liposome platform technology (DPT) development. The Company’s development program is focused on improving and optimizing LPT characterization methods and scaling capabilities.

Innocan believes that scaling up production capabilities will enable Innocan to move forward with planned experiments and could serve as a basis for technology transfer for GMP production, which is a fundamental need to achieve the human clinical trials. A team of 6 people (scientists and scientific assistants) is currently working on the accelerated development of the LPT technology.

The company previously announced that previous studies of sustained-release cannabidiol (CBD) from liposomes injected subcutaneously into dogs showed continuous and significant blood levels of CBD for at least six weeks after a single administration. . These results are a significant advance in the development of the technology, demonstrating the benefits of LPT in dogs, which may serve as a good prediction of the behavior of LPT in humans.

“Early results from our LPT animal trials were so promising that we decided to step up a gear, moving closer to our goal of reaching commercialization and becoming the world leader in CBD drug development,” said said Iris Bincovich, CEO of Innocan Pharma and added “We are proud of our cooperation with the Hebrew University of Jerusalem and to be able to partner with leading scientific institutions in Israel.”

Innocan’s relationship with the Hebrew University

Innocan Israel has entered into a research and licensing agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, regarding the design, preparation, characterization and evaluation of liposomes loaded with CBD (or other cannabinoids) . The research and development initiative is led by Professor Chezy Barenholz, head of the Hebrew University’s Department of Membrane and Liposome Research, who is the inventor of more than fifty-five patent families, including two under -tend Doxil®, an FDA-approved drug for the treatment of breast cancer. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation, and central nervous system disorders. A patent was filed covering this technology on October 7, 2019.

About Innocan

Innocan Pharma is a pharmaceutical technology company focused on developing multiple drug delivery platforms containing CBD. Innocan Pharma and Ramot of Tel Aviv University are collaborating on a breakthrough new exosome-based technology that targets both central nervous system (CNS) indications and the corona virus Covid-19 using CBD. CBD-loaded exosomes have the potential to aid in the recovery of infected lung cells. This product, which should be administered by inhalation, will be tested against various lung infections.

Innocan Pharma has signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled-release liposome to be administered by injection. Innocan Israel plans, in collaboration with Professor Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceutical products, including but not limited to topical treatments for the relief of symptoms of psoriasis as well as the treatment of muscle pain and rheumatic pain. The founders and leaders of Innocan Israel each have successful business experience in the pharmaceutical and technology sectors in Israel and around the world.

For more information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

Lytham Partners, LLC
Ben Shamsian CPA | vice president

Direct: 646-829-9701; Cell: 516-652-9004

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED NOR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information presented in this press release, including, without limitation, information regarding the success of its research activities, collaborations, potential treatments from the use of the Company’s LPT technology, research subsequent treatments for other conditions, treatment of other conditions and other therapeutic effects resulting from the Company’s research activities and/or products, required regulatory approvals and timing of market entry, constitutes forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this press release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions regarding the anticipated benefits of the products, the satisfaction of regulatory requirements in various jurisdictions and the satisfactory completion of production agreements. and distribution required. .

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this press release. Principal risks and uncertainties include, but are not limited to: general global and local (national) economic, business and business conditions; governmental and regulatory requirements and actions of governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks inherent in the nature of product distribution, including import/export issues and the inability to obtain required regulatory and other approvals (or to do so in a timely manner) and availability on each market for product inputs and finished products. some products. The expected timeline for market entry may change for a number of reasons, including the inability to secure necessary regulatory requirements or the need for additional time to enter into and/or satisfy manufacturing and distribution agreements. . Based on the foregoing, readers should not place undue reliance on any forward-looking information contained in this press release regarding the timing of the launch of product distribution. A detailed discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned not to place undue reliance on forward-looking information, as actual results may differ materially from the forward-looking information. Innocan does not undertake to update, correct or revise forward-looking information as a result of new information, future events or otherwise, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/110493

Comments are closed.